BeiGene (BGNE) Highlights Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkin’s Lymphoma
Tweet Send to a Friend
BeiGene, Ltd. (NASDAQ: BGNE) today presented preliminary clinical data from an ongoing Phase 1b trial of its investigational Bruton’s Tyrosine ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
